Ibrexafungerp Citrate
FDA-approved product (tablet, oral), marketed as Brexafemme.
- Registered studies
- 0
- Lab records
- 0
- Pathogens at ≥40%
- 4 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Vulvovaginal candidiasis
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Other antimycotics for systemic use
- Anti-infective classification
- Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J02AX07
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA63.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli49.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae44.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- M. tuberculosis46.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
No evidence found
The registry was searched and no registered study names this medicine.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Ibrexafungerp Citrate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- BaricitinibExisting use: Rheumatoid arthritis53.9% AI-predicted activityagainst MRSA50+ registered studies
- Metocurine IodideExisting use: Curare alkaloids53.8% AI-predicted activityagainst MRSANo documented evidence found
- Paramethasone AcetateExisting use: Glucocorticoids53.8% AI-predicted activityagainst MRSANo documented evidence found
- Mivacurium ChlorideExisting use: Other quaternary ammonium compounds53.8% AI-predicted activityagainst MRSA14 registered studies
- HalazepamExisting use: Anxiety53.6% AI-predicted activityagainst MRSANo documented evidence found
- OmaveloxoloneExisting use: Friedreich ataxia53.6% AI-predicted activityagainst MRSA25 registered studies
- Topotecan HydrochlorideExisting use: Carcinoma, Cervical adenocarcinoma, Cervical cancer and 5 more53.6% AI-predicted activityagainst MRSA50+ registered studies
- DesonideExisting use: Atopic eczema, Eye inflammation, Skin disease53.5% AI-predicted activityagainst MRSA13 registered studies
- Dabigatran Etexilate MesylateExisting use: Atrial fibrillation, Deep vein thrombosis, Pulmonary embolism and 5 more53.5% AI-predicted activityagainst MRSA14 registered studies
- Triamcinolone DiacetateExisting use: Airway obstruction, Eye inflammation, Hemorrhoid and 2 more53.5% AI-predicted activityagainst MRSA50+ registered studies
- CapivasertibExisting use: Breast cancer, Breast neoplasm, Cancer and 1 more53.4% AI-predicted activityagainst MRSA50+ registered studies
- Vecuronium BromideExisting use: Other quaternary ammonium compounds53.3% AI-predicted activityagainst MRSA50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
No evidence found: the registry was searched and no registered study names this medicine.